novartis institutes for biomedical research

• Health Tech
• Health Insurance
• Medical Devices
• Gene Therapy
• Neuroscience
• H5N1 Bird Flu
• Health Disparities
• Infectious Disease
• Mental Health
• Cardiovascular Disease
• Chronic Disease
• Alzheimer's
• Coercive Care
• The Obesity Revolution
• The War on Recovery
• Adam Feuerstein
• Matthew Herper
• Jennifer Adaeze Okwerekwu
• Ed Silverman
• CRISPR Tracker
• Breakthrough Device Tracker
• Generative AI Tracker
• Obesity Drug Tracker
• 2024 STAT Summit
• All Summits
• STATUS List
• STAT Madness
• STAT Brand Studio

Don't miss out

Subscribe to STAT+ today, for the best life sciences journalism in the industry

Why Novartis is changing the name of its research labs

By Jonathan Wosen Sept. 8, 2023

S wiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

advertisement

But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit . The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to stat+..

Totals $468 per year

for 3 months, then $399/year

Then $399/year

Savings start at 25%!

Annually per user

$300 Annually per user

Get unlimited access to award-winning journalism and exclusive events.

About the Author Reprints

Jonathan wosen.

West Coast Biotech & Life Sciences Reporter

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter.

drug development

STAT Future Summit

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page .

Recommended

Recommended Stories

STAT Plus: UnitedHealth pledged a hands-off approach after buying a Connecticut medical group. Then it upended how doctors practice

STAT Plus: The weight loss drug shortage is driving patients to Hims. What happens when the shortage ends?

STAT Plus: Wegovy cut patients’ chances of dying from Covid-19, new analysis shows

STAT Plus: Sanofi says its new pill for multiple sclerosis succeeded in a key trial, boosting its research ambitions

STAT Plus: Trump keeps losing his train of thought. Cognitive experts have theories about why

Massachusetts Biotechnology Council

Member Directory

Novartis institutes for biomedical research.

Novartis Institutes for BioMedical Research is Novartis global research organization and is committed to discovering innovative medicines that cure disease and improve human health. By conducting more relevant and predictable drug discovery that can yield new and better medicines for patients, Novartis Institutes for BioMedical Research is redefining drug discovery in the post-genomic era. Over the past four years, Novartis Pharmaceuticals has had the greatest number of new molecular entities approved by the US FDA. With its broad focus on diseases for which there is a need for better medical therapies, and with 3,000 talented, dedicated research scientists worldwide, Novartis Institutes for BioMedical Research is well-positioned to ensure Novartis maintains its strong pipeline and highly successful track record in new drug discovery.> Novartis Institutes has sites in Cambridge, Massachusetts (headquarters); Basel, Switzerland; Horsham, UK; East Hanover, NJ; Vienna, Austria; and Tsukuba, Japan. Novartis Institutes Cambridge facilities encompass 750,000 square feet of laboratory and office space. Research in cardiovascular disease, oncology, infectious disease, diabetes, ophthalmology and skeletal muscle disease is headquartered in Cambridge. In addition, Cambridge is home to the following platform technologies: Global Discovery Chemistry, Functional Genomics, Developmental & Molecular Pathways, and Models of Disease Center.

See all Members

Novartis Institutes for BioMedical Research Cambridge Campus

An innovation engine for biomedical breakthroughs

Located at the heart of the Boston area innovation ecosystem, the Novartis Institutes for BioMedical Research (NIBR) complex is transforming the way scientists perform their ground-breaking work. Known as the innovation engine of the global Novartis organization, the NIBR is tasked with discovering new medicines for some of the most challenging health issues in the world.

Once located in disparate locations, the multi-building campus brings more than 1,000 top researchers together to spur increased collaboration, idea-sharing and teamwork. Novartis is using this complex to create a new paradigm—one that creates a dynamic workplace that breaks down the walls between disciplines, both figurative and literal, blurs the boundaries between discovery and commercialization, bridges geographies, and fundamentally changes its approach to science.

Maya Lin designed the overall masterplan and the building known as 181 Massachusetts Avenue. Toshiko Mori designed the second building, 22 Windsor Street, and Michael Van Valkenburgh designed the expansive courtyard. CannonDesign served as the architect of record, science/laboratory design firm, and design engineer for the entire complex.  

Enhancing the new scientific workplace

The Novartis complex challenges what the traditional research model functions and looks like through unique design solutions, from the design aesthetic found throughout to the enriched laboratory environments, and the highest focus on sustainability, culture and community.

One of the design goals for the project was to present the buildings as penetrable to pedestrians and responsive to the surrounding context. Rather than build one massive structure, the complex consists of a community of buildings demonstrating that functional labs can be housed within beautiful and inspirational architecture.

Designed for research

Throughout the new research buildings, occupants encounter an overwhelming sense of openness. Expansive windows offer framed views of the outside, and voluminous atriums and open stairways span the height of the buildings. Knowing that teamwork and “heads down” work can take place in many settings, multiple workplace modes and venues are found throughout—from a 350-seat auditorium and large conference rooms to intimate huddle spaces, workstations, lounges and communal areas.

In the laboratories, collaboration is promoted by eliminating overhead casework and barriers between researchers; sightlines are clear and the equipment typically found cluttering benchtops is housed in centralized areas called Tech Zones. A just-in-time delivery system ensures researchers have the tools they need, and breakout rooms are incorporated into most laboratory environments to prevent researchers from having to leave the lab to work together.

Sustainably developed

The overall site dramatically improves the connection between Central Square and the Charles River by filling a once-barren strip of asphalt and concrete with dynamic uses and landscaping. Green roofs, storm water collection and reuse, external shading, sustainable materials, high-efficiency lab equipment and engineering systems, and more helped the project achieve LEED Gold certification. Taking a "whole building" approach to sustainability, the research complex is compliant with the EPA’s Labs21 Environmental Performance Criteria 2.0.

Community impact

To strengthen its role as a good civic neighbor, the building employs a number of features focused on positive community impact. The 1.35-acre courtyard at the center of the complex creates a diagonal pedestrian shortcut across the site and a publicly accessible campus-like environment filled with trees, seating and meandering pathways. Glass walls at the street level enhance the interaction between the buildings and the public, and more than 8,000 square feet of retail space welcomes pedestrians inside. On the ground floor of 22 Windsor Street, a Community Exploration and Learning Lab is dedicated to engaging middle and high school students in biomedical science.

Explore more

Centre hospitalier de l’université de montréal.

Setting a city’s future healthcare vision in motion

CJ Corporation, CJ Blossom Park

Creating the “Only One” research center

Work details overlay

Work details, distinctions, special recognition award, laboratory of the year, 2017, higher education best project award, engineering news-record new england, 2016.

Architecture

Interior Design

Lighting Design

MEP Engineering

Structural Engineering

Engineering

Laboratory Design

Sustainability Services

Technology Solutions

Collaborators

Maya lin studios.

Design Architect for 181 Massachusetts Avenue

Toshiko Mori Architect

Design Architect for 22 Windsor Street

Michael Van Valkenburgh

Landscape & Site Design

• This is Broad Learn about our mission, our values, our history, and partner institutions.
• People Meet our members, staff scientists, fellows, leadership, and other Broadies.
• Join Broad Find out how to join the Broad as an employee or associate member.
• Contact us Find our contact information, directions to our buildings, and directory.
• Broad@20 Broad turns 20 this year! See how we’re celebrating our 20th anniversary.
• Cardiovascular disease
• Brain Health
• Infectious disease and microbiome
• Kidney disease
• Rare disease
• Chemical biology and therapeutics science
• Drug discovery
• Genome regulation, cellular circuitry, and epigenomics
• Medical and population genetics
• Data sciences
• Genetic perturbation
• Metabolomics
• Spatial technologies
• Patient-partnered research Patients partner with our scientists to accelerate the pace of discovery and find better treatments.
• Partnering and licensing We work closely with pharmaceutical, biotech, and technology partners to accelerate the translation of our discoveries.
• Publications A catalog of scientific papers published by our members and staff scientists.
• Resources, services, and tools Key scientific datasets and computational tools developed by our scientists and their collaborators.
• Collaborations and consortia We join with institutions and scientists the world over to address foundational challenges in science and health.
• Carlos Slim Center for Health Research The Slim Center aims to bring the benefits of genomics-driven medicine to Latin America, gleaning new insights into diseases with relevance to the region.
• Gerstner Center for Cancer Diagnostics The Gerstner Center is developing next-generation diagnostic technology for cancer detection and tracking disease progression.
• Klarman Cell Observatory The Klarman Cell Observatory is systematically defining mammalian cellular circuits, how they work together to create tissues and organs, and are perturbed to cause disease.
• Merkin Institute for Transformative Technologies in Healthcare The Merkin Institute is supporting early-stage ideas aimed at advancing powerful technological approaches for improving how we understand and treat disease.
• Novo Nordisk Foundation Center for Genomic Mechanisms of Disease This center is developing new paradigms and technologies to scale the discovery of biological mechanisms of common, complex diseases, by facilitating close collaborations between the Broad Institute and the Danish research community.
• Eric and Wendy Schmidt Center The EWSC is catalyzing a new field of interdisciplinary research at the intersection of data science and life science, aimed at improving human health.
• Stanley Center for Psychiatric Research The Stanley Center aims to reduce the burden of serious mental illness by contributing new insights into pathogenesis, identifying biomarkers, and paving the way toward new treatments.
• Art and science connection Explore the connection between art and science and how we bring together artists and Broad scientists through our artist-in-residence program, gallery exhibitions, and ongoing public conversations.
• Broad Discovery Center Visit our free public educational space that showcases how researchers at the Broad and their colleagues around the world seek to understand and treat human disease.
• Learning resources Access free classroom materials and more for STEM educators, parents, students, tutors, and others.
• Public programs Discover remarkable stories of scientific progress, and explore the intersections of science, medicine, and society.
• Student opportunities Learn about Broad Institute's mentored research offerings for high school students, college students, and recent college graduates.
• Visit Broad Come see what Broad is all about.
• Sign up for our newsletter Receive regular updates on Broad news, research and community.

Diabetes Genetics Initiative

The Diabetes Genetics Initiative is a collaboration of the Broad Institute of MIT and Harvard, Lund University, and Novartis Institutes for BioMedical Research

The Diabetes Genetics Initiative combines the resources and expertise of the Novartis Institutes for BioMedical Research, the Broad Institute of MIT and Harvard, and Lund University to identify the genetic determinants of type 2 diabetes. This unique collaboration aims to collect and analyze samples from type 2 diabetic patients from nations across the globe, performing whole genome scans to provide a comprehensive view of the DNA sequence variants associated with the disease. This partnership has been forged with the explicit goal of making this vast amount of crucial data available to researchers globally and free of cost, which should lead to a greater understanding of disease biology and speed the development of more effective therapies.

Whole genome scan for type 2 diabetes in a Scandinavian cohort

The goal of this project is to identify inherited risk factors that predispose individuals to type 2 diabetes by performing a whole genome association study in approximately 3,000 individuals from Scandinavia, using the Affymetrix Human Mapping 500K GeneChip®.

Publication in Science : Genome-wide search unearths surprising clues for diabetes and blood triglycerides (04/26/07)

DIAGRAM Consortium: Results from type 2 diabetes meta-analysis Zeggini E, Scott LJ, Saxena R, Voight BF for the DIAGRAM consortium. Meta-analysis of genome-wide association data and large-scale replication identifies several additional susceptibility loci for type 2 diabetes. Nature Genetics in press.

Family-based linkage scan in three pedigrees with extreme diabetes phenotypes

The goal of this project is to identify chromosomal loci linked to diabetes in three Scandinavian families with clustering of early-onset diabetes using the Affymetrix Human Mapping 500K GeneChip® (10,116 SNPs).

A whole genome admixture scan for type 2 diabetes in African Americans

The goal of this project is to perform a whole genome admixture scan in 1,976 African Americans from the Jackson Heart Study and the Multi-Ethnic Cohort, aiming to localize susceptibility loci for type 2 diabetes.

Areas of Focus

• Genetic Basis of Type 2 Diabetes (T2D) and T2D-related Traits
• Functional Characterization of T2D-associated Genes and Pathways
• Translation of Genetic Information to Clinical Practice
• Chemical Biology of Diabetes
• Lund University

Latest news

City of San Diego Official Website

Accessibility Tools

Audio/Vision Assist:

Turn On/Off

High Contrast:

More Info on accessibility

Environmental Services

• Environmental Services Home
• Collection Services
• Miramar Landfill & Greenery
• Recycling Programs
• Hazardous Waste

Genomics Institute of the Novartis Research

Serves as a bridge between basic science and preclinical drug discovery for Novartis' global research organization, the Novartis Institutes for BioMedical Research (NIBR).

Contact Info

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• An Audience With
• Published: 30 March 2017

Jay Bradner

Nature Reviews Drug Discovery volume  16 ,  pages 232–233 ( 2017 ) Cite this article

5643 Accesses

2 Citations

32 Altmetric

Metrics details

• Business strategy in drug development
• Drug development
• Drug therapy
• Small molecules

An Erratum to this article was published on 18 April 2017

This article has been updated

In 2015, the haematologist Jay Bradner made the leap from supervising a few dozen researchers in his lab at the Dana-Farber Cancer Institute to overseeing more than 6,000 scientists at Novartis. As president of the Novartis Institutes for BioMedical Research (NIBR), he has now rolled out his vision for NIBR 2.0 — with an increased focus on chemical biology and open science. He spoke with Asher Mullard about his plans to restructure around emerging drug discovery tools and to forge closer ties with the rest of the scientific community.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?

• Alexander Schuhmacher
• , Oliver Gassmann
•  …  Markus Hinder

Journal of Translational Medicine Open Access 08 May 2018

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

195,33 € per year

only 16,28 € per issue

Buy this article

• Purchase on SpringerLink
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Change history

18 april 2017.

Two typographical errors that may have affected the meaning of the answers related to the creation of the Chemical Biology & Therapeutics unit within NIBR and the focus of the NIBR leadership on open science have been corrected.

Rights and permissions

Reprints and permissions

About this article

Cite this article.

Jay Bradner. Nat Rev Drug Discov 16 , 232–233 (2017). https://doi.org/10.1038/nrd.2017.50

Download citation

Published : 30 March 2017

Issue Date : April 2017

DOI : https://doi.org/10.1038/nrd.2017.50

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

This article is cited by

Open innovation and external sources of innovation. an opportunity to fuel the r&d pipeline and enhance decision making.

• Oliver Gassmann
• Markus Hinder

Journal of Translational Medicine (2018)

Erratum: An audience with Jay Bradner

• Asher Mullard

Nature Reviews Drug Discovery (2017)

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Dezeen Magazine dezeen-logo dezeen-logo

Toshiko Mori and Maya Lin create buildings for Boston pharmaceutical campus

Architects  Toshiko Mori , Maya Lin and CannonDesign teamed up to design this new  research complex for Swiss drug company Novartis, located in the Boston area.

The complex, called the Novartis Institutes for BioMedical Research, is located on a busy street in Cambridge, near the campus for the Massachusetts Institute of Technology . Encompassing more than 800,000 square feet (74,322 square metres), the complex brings together over 1,000 pharmaceutical researchers.

"The overarching goal for the project was to create an ideal work environment for research, with specific emphasis on increasing the exchange of knowledge and levels of interdisciplinary collaboration," said US-based CannonDesign , which served as the project’s architect of record.

The urban complex consists of two connected buildings, which wrap a courtyard designed by Michael Van Valkenburgh Associates , a Brooklyn -based landscape architecture firm. An underground parking garage is hidden beneath.

Occupying one corner of the campus is the 181 Massachusetts Avenue building, conceived by designer Maya Lin in association with New York architecture firm Bialosky + Partners Architects .

L-shaped in plan, the building consists of two distinct volumes: a tall, rectilinear portion that contains laboratories, and a lower, curved portion that houses offices, meetings rooms, and an auditorium.

"The design of the building maintains the human scale of the adjacent buildings at street level while creating a taller space for research labs set back from the street," Lin explained on her studio's website .

The lower portion is wrapped with a distinctive screen made of light-coloured stone. Its appearance was inspired by "microscopic views of organic coral or bone structure".

The curtain wall behind the screen is composed of five different hues of glass that mathematically correspond to the openings in the stone brise-soleil.

"Conceptually I felt this translation of nature through a systematic and mathematical process reflects back on how science and medicine take materials found in nature and, through scientific analysis and research, transform them into new medicinal compounds," Lin stated.

Lin’s building is linked to 22 Windsor Street, a research facility designed by  Toshiko Mori 's New York studio – whose impressive portfolio includes a  cultural centre in Senegal  and an extension to a Marcel Breuer-designed house .

Rectangular in plan, the glazed building features glass louvres with copper mesh interlayers, which help shade sensitive laboratory zones. On the southern facade, protrusions framed in stone denote communal areas.

"Social spaces are expressed by large stone frames, enlivening the southern facade in a dialogue with the campus, community and city," states a description on Mori’s website .

For the interior of the two buildings, the team focused on creating flexible spaces with minimal columns and broad sight lines. "Specialised functions and tech zones are grouped around core laboratory equipment to further eliminate visual obstacles in the labs," said CannonDesign.

To help inform the interior design, the team created a full-scale, experimental mockup in a nearby vacant space to test new organisational and physical models.

"This resulted in research environments that were applied to this complex, as well as to many other existing Novartis research facilities worldwide," the team said.

Photography is by  Esto Photographics Inc and Anton Grassl.

Project credits: 

Design architect for 181 Massachusetts Avenue: Maya Lin Studio with Bialosky + Partners Architects Design architect for 22 Windsor Street: Toshiko Mori Architect Architect of record, structural engineering and MEP: CannonDesign Landscape architect: Michael Van Valkenburgh Associates Engineering: Nitsch Engineering Contractor: Skanska USA Building Inc

• Massachusetts
• Architecture
• Toshiko Mori
• Office architecture
• Laboratories

Subscribe to our newsletters

A quarterly newsletter rounding up a selection of recently launched products by designers and studios, published on Dezeen Showroom. 

Our most popular newsletter, formerly known as Dezeen Weekly, is sent every Tuesday and features a selection of the best reader comments and most talked-about stories. Plus occasional updates on Dezeen’s services and breaking news. 

Sent every Thursday and containing a selection of the most important news highlights. Plus occasional updates on Dezeen’s services and invitations to Dezeen events. 

A daily newsletter containing the latest stories from Dezeen.

Daily updates on the latest design and architecture vacancies advertised on Dezeen Jobs. Plus occasional news.

Weekly updates on the latest design and architecture vacancies advertised on Dezeen Jobs. Plus occasional news.

News about our Dezeen Awards programme, including entry deadlines and announcements. Plus occasional updates.

News from Dezeen Events Guide, a listings guide covering the leading design-related events taking place around the world. Plus occasional updates and invitations to Dezeen events.

News about our Dezeen Awards China programme, including entry deadlines and announcements. Plus occasional updates.

We will only use your email address to send you the newsletters you have requested. We will never give your details to anyone else without your consent. You can unsubscribe at any time by clicking on the unsubscribe link at the bottom of every email, or by emailing us at [email protected] .

For more details, please see our privacy notice .

You will shortly receive a welcome email so please check your inbox.

You can unsubscribe at any time by clicking the link at the bottom of every newsletter.

Working together, we can reimagine medicine to improve and extend people’s lives.

Senior Scientist, Comparative Medicine- Research Collaborations

About the role.

Your Key Responsibilities:

• Actively participate in scientific discussions, performing critical review of experimental protocols and identifying the best approach for in vivo studies according to project needs. • Schedule, perform and coordinate state-of-the-art animal experimentation and data interpretation with the highest ethical and technical standards, setting up and validating animal models independently and/or together with BR scientific project teams. • High level technical expertise with experience in developing novel animal models (Rodent and USDA species). • Be an excellent team player and show potential to lead associates, ensuring appropriate performance, training, and professional development of the associates. Identify and coach high and low performers (leadership experience advantageous) • Responsible for ensuring team compliance with all institutional and regulatory protocols, policies, and guidelines.

Role Requirements :

Some weekend on call, holiday coverage required. • Bachelor or Master’s in Biomedical Sciences or equivalent experience, • Minimum 5+ years of experience in a technical skills tract laboratory animal program • Strong commitment to animal welfare, research support, and high quality in vivo focused science • Strong communication with a broad range of stakeholders, strong aptitudes as team player. • Strong leadership skill base and prior experience of leading a small team of research associates, preferred. • Responsible for pursuing continuous learning/professional development opportunities, enhancing/expanding skill set, and reviewing CM techniques. • Fluency in English. • Must be able to lift 50 lbs., be able to work from a standing position for prolonged periods of time and perform repetitive motion tasks.

Commitment to Diversity & Inclusion: The Novartis Group of Companies are Equal Opportunity Employers and take pride in maintaining a diverse environment. We do not discriminate in recruitment, hiring, training, promotion or other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, gender identity or expression, marital or veteran status, disability, or any other legally protected status. We are committed to building diverse teams, representative of the patients and communities we serve, and we strive to create an inclusive workplace that cultivates bold innovation through collaboration and empowers our people to unleash their full potential.

Novartis Compensation and Benefit Summary: The pay range for this position at commencement of employment is expected to be between $97,600- $146,400/year ; however, w hile salary ranges are effective from 1/1/24 through 12/31/24, fluctuations in the job market may necessitate adjustments to pay ranges during this period.  Further, final pay determinations will depend on various factors, including, but not limited to geographical location, experience level, knowledge, skills, and abilities. The total compensation package for this position may also include other elements, including a sign-on bonus, restricted stock units, and discretionary awards in addition to a full range of medical, financial, and/or other benefits (including 401(k) eligibility and various paid time off benefits, such as vacation, sick time, and parental leave), dependent on the position offered. Details of participation in these benefit plans will be provided if an employee receives an offer of employment. If hired, employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance, Company or individual department/team performance, and market factors

Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each other. Combining to achieve breakthroughs that change patients’ lives. Ready to create a brighter future together? https://www.novartis.com/about/strategy/people-and-culture

Join our Novartis Network: Not the right Novartis role for you? Sign up to our talent community to stay connected and learn about suitable career opportunities as soon as they come up: https://talentnetwork.novartis.com/network

Benefits and Rewards: Read our handbook to learn about all the ways we’ll help you thrive personally and professionally: https://www.novartis.com/careers/benefits-rewards

EEO Statement:

The Novartis Group of Companies are Equal Opportunity Employers who are focused on building and advancing a culture of inclusion that values and celebrates individual differences, uniqueness, backgrounds and perspectives. We do not discriminate in recruitment, hiring, training, promotion or other employment practices for reasons of race, color, religion, sex, national origin, age, sexual orientation, gender identity or expression, marital or veteran status, disability, or any other legally protected status. We are committed to fostering a diverse and inclusive workplace that reflects the world around us and connects us to the patients, customers and communities we serve.

Accessibility & Reasonable Accommodations

The Novartis Group of Companies are committed to working with and providing reasonable accommodation to individuals with disabilities. If, because of a medical condition or disability, you need a reasonable accommodation for any part of the application process, or to perform the essential functions of a position, please send an e-mail to [email protected] or call +1(877)395-2339 and let us know the nature of your request and your contact information. Please include the job requisition number in your message.